Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01010399 · ClinicalTrials.gov registry record · Phase 4
Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
A Phase 4 study of HIV Infection and Hypertriglyceridemia, sponsored by Felizarta, Franco, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT01010399 is a Phase 4 study of HIV Infection and Hypertriglyceridemia that has completed, run by Felizarta, Franco, M.D.. The registered enrollment target is 36 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01010399, a Phase 4 study of HIV Infection and Hypertriglyceridemia, has completed, sponsored by Felizarta, Franco, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dL while maintaining virologic suppression.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Lovaza
- DRUG fosamprenavir/ritonavir
Study Locations (1)
California
- Franco Felizarta, MD - Bakersfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2009-09 |
| Est. Completion | 2010-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01010399
The ClinicalTrials.gov registry entry for NCT01010399 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (85% lower). The listed sponsor is Felizarta, Franco, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 2 interventions - of which Lovaza is the first listed.
NCT01010399 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01010399 about?
NCT01010399 is a clinical study titled "Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects". In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result in 30% of patients achieving a reduction in fasting triglycerides \< 200 mg /dL while maintaining virologic suppressi...
What is the current status of trial NCT01010399?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2009-09. Estimated completion is 2010-11.
What conditions does trial NCT01010399 study?
This clinical trial studies the following conditions: HIV Infection, Hypertriglyceridemia.
What interventions are being tested in trial NCT01010399?
The interventions under investigation include: Lovaza (DIETARY_SUPPLEMENT), fosamprenavir/ritonavir (DRUG).
Who is sponsoring clinical trial NCT01010399?
This trial is sponsored by Felizarta, Franco, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01010399 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MAPS PrEP Van Study
RECRUITING · Phase 4
-
Improving Immunogenicity of Influenza Vaccine in HIV Infected Individuals
COMPLETED · Phase 4
-
A Multicenter Study to Assess the Tolerability of Once Daily Lopinavir/Ritonavir (LPV/r) Liquid Versus Capsules
COMPLETED · Phase 4
-
IMPAACT 1077HS: Examining Benefits of HAART Continuation in Postpartum Women
COMPLETED · Phase 4
-
Safety and Efficacy Study of Switching From Epzicom to Truvada
COMPLETED · Phase 4
-
A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence
COMPLETED · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.